Jazz Pharmaceuticals (JAZZ) Liabilities and Shareholders Equity (2016 - 2025)
Jazz Pharmaceuticals (JAZZ) has 16 years of Liabilities and Shareholders Equity data on record, last reported at $11.7 billion in Q4 2025.
- For Q4 2025, Liabilities and Shareholders Equity fell 2.94% year-over-year to $11.7 billion; the TTM value through Dec 2025 reached $45.5 billion, up 27.81%, while the annual FY2025 figure was $11.7 billion, 2.94% down from the prior year.
- Liabilities and Shareholders Equity reached $11.7 billion in Q4 2025 per JAZZ's latest filing, up from $11.4 billion in the prior quarter.
- Across five years, Liabilities and Shareholders Equity topped out at $13.2 billion in Q2 2021 and bottomed at $6.8 billion in Q1 2021.
- Average Liabilities and Shareholders Equity over 5 years is $11.3 billion, with a median of $11.4 billion recorded in 2025.
- Peak YoY movement for Liabilities and Shareholders Equity: skyrocketed 117.8% in 2021, then fell 16.78% in 2022.
- A 5-year view of Liabilities and Shareholders Equity shows it stood at $12.3 billion in 2021, then decreased by 11.9% to $10.8 billion in 2022, then increased by 5.15% to $11.4 billion in 2023, then increased by 5.43% to $12.0 billion in 2024, then dropped by 2.94% to $11.7 billion in 2025.
- Per Business Quant database, its latest 3 readings for Liabilities and Shareholders Equity were $11.7 billion in Q4 2025, $11.4 billion in Q3 2025, and $10.9 billion in Q2 2025.